Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 553

1.

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.

Eyre TA, Khan D, Hall GW, Collins GP.

Eur J Haematol. 2014 Dec;93(6):455-68. doi: 10.1111/ejh.12360. Epub 2014 May 21. Review.

PMID:
24766435
2.

Anaplastic large cell lymphoma, ALK-negative.

Ferreri AJ, Govi S, Pileri SA, Savage KJ.

Crit Rev Oncol Hematol. 2013 Feb;85(2):206-15. doi: 10.1016/j.critrevonc.2012.06.004. Epub 2012 Jul 11. Review.

3.

Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.

Foyil KV, Bartlett NL.

Cancer J. 2012 Sep-Oct;18(5):450-6. Review.

PMID:
23006951
4.

Anaplastic large cell lymphoma, ALK-positive.

Ferreri AJ, Govi S, Pileri SA, Savage KJ.

Crit Rev Oncol Hematol. 2012 Aug;83(2):293-302. doi: 10.1016/j.critrevonc.2012.02.005. Epub 2012 Mar 21. Review.

PMID:
22440390
5.
6.

The biology and management of systemic anaplastic large cell lymphoma.

Hapgood G, Savage KJ.

Blood. 2015 Jul 2;126(1):17-25. doi: 10.1182/blood-2014-10-567461. Epub 2015 Apr 13. Review.

7.

ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.

Huang L, Zhang F, Zeng J, Guo H, Liu S, Wei X, Chen F, Jiang X, Liang Z, Liu Y, Li W.

Ann Hematol. 2018 Jan;97(1):149-159. doi: 10.1007/s00277-017-3166-8. Epub 2017 Nov 17.

PMID:
29150811
8.

Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.

Oregel KZ, Everett E, Zhang X, Nagaraj G.

Expert Rev Anticancer Ther. 2016;16(3):279-83. doi: 10.1586/14737140.2016.1146597. Epub 2016 Feb 18.

PMID:
26809026
9.

Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.

Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM.

Oncology (Williston Park). 2010 Jun;24(7):574-87. Review.

10.

Anaplastic large cell lymphoma: a single institution experience from India.

Lakshmaiah KC, Guruprasad B, Shah A, Kavitha S, Abraham LJ, Govindbabu K, Aruna Kumari BS, Appaji L.

J Cancer Res Ther. 2013 Oct-Dec;9(4):649-52. doi: 10.4103/0973-1482.126468.

11.

Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.

Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG.

Leukemia. 2000 Sep;14(9):1533-59. Review.

PMID:
10994999
12.
13.

The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.

Atsaves V, Lekakis L, Drakos E, Leventaki V, Ghaderi M, Baltatzis GE, Chioureas D, Jones D, Feretzaki M, Liakou C, Panayiotidis P, Gorgoulis V, Patsouris E, Medeiros LJ, Claret FX, Rassidakis GZ.

Br J Haematol. 2014 Nov;167(4):514-23. doi: 10.1111/bjh.13079. Epub 2014 Aug 22.

PMID:
25145835
14.

Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.

Boi M, Zucca E, Inghirami G, Bertoni F.

Br J Haematol. 2015 Mar;168(6):771-83. doi: 10.1111/bjh.13265. Epub 2015 Jan 6. Review.

PMID:
25559471
15.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM.

Lancet Oncol. 2013 May;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. Epub 2013 Apr 16.

16.

[Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study].

Shi Y, Chen G, Zhou XG, Gong LP, Yu R, Zheng YY, Xie JL, Jin Y.

Zhonghua Bing Li Xue Za Zhi. 2010 Apr;39(4):235-9. Chinese.

PMID:
20654121
17.

Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients.

Wang YF, Yang YL, Gao ZF, Zhou CJ, Gregg X, Shi YF, Wang J, Yang XF, Ke XY.

J Hematol Oncol. 2012 Jul 7;5:38. doi: 10.1186/1756-8722-5-38.

18.

Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.

Werner MT, Zhao C, Zhang Q, Wasik MA.

Blood. 2017 Feb 16;129(7):823-831. doi: 10.1182/blood-2016-05-717793. Epub 2016 Nov 22. Review.

20.

Supplemental Content

Support Center